CHICAGO (Reuters) - The president of U.S. pharmaceuticals at GlaxoSmithKline Plc , Chris Viehbacher, said on Wednesday it was too early to write off the diabetes drug Avandia, which he said could once again return to annual sales of more than $3 billion.
More...